APOE & Alzheimer’s: Microglia Impact by Gene Variant
- A new study published in Nature Communications sheds light on how different versions of the apolipoprotein E (APOE) gene impact the function of microglia, the brain's immune cells,...
- Alzheimer's, the leading cause of dementia in the United Kingdom, affects 1 in 14 individuals over 65. The disease is characterized by the accumulation of amyloid plaques and...
- The APOE gene is a major genetic risk factor; its variants,APOE2,APOE3,and APOE4,carry different risks.
Explore how the APOE gene impacts Alzheimer’s disease, with a focus on microglia function. A new study reveals that different versions of the APOE gene—APOE2, APOE3, and APOE4—considerably alter microglial behaviour, the brain’s immune cells. Specifically, APOE4 impairs microglia’s protective functions, while APOE2 enhances them. The research highlights that tailored treatments based on a patient’s APOE genotype are crucial. The study also found a connection between vitamin D receptor activity and APOE2, suggesting a potential link to reduced Alzheimer’s risk. News Directory 3 is on the case, bringing you the latest in Alzheimer’s research. Discover what’s next in targeted therapies and preventative strategies.
Study Uncovers APOE Gene’s Role in Alzheimer’s Microglia Function
Updated May 28, 2025
A new study published in Nature Communications sheds light on how different versions of the apolipoprotein E (APOE) gene impact the function of microglia, the brain’s immune cells, in Alzheimer’s disease.The research, conducted at the UK Dementia Research Institute at King’s College London, emphasizes the need for tailored treatments based on individual APOE genotypes.
Alzheimer’s, the leading cause of dementia in the United Kingdom, affects 1 in 14 individuals over 65. The disease is characterized by the accumulation of amyloid plaques and tau tangles in the brain.
The APOE gene is a major genetic risk factor; its variants,APOE2,APOE3,and APOE4,carry different risks. APOE4 elevates the risk of Alzheimer’s, while APOE2 is associated with a lower risk. The mechanisms behind these varying risk profiles have remained unclear.
Researchers focused on the APOE gene’s role in microglia. As the three APOE versions are unique to humans,direct study in mouse brains is impractical. To circumvent this,they developed a human “xenotransplantation model.” Human microglia,grown from stem cells and engineered to express different APOE versions,where transplanted into the brains of mice with amyloid plaques. The microglia were then analyzed for gene expression and chromatin accessibility.
The study revealed significant changes in the transcriptomic and chromatin landscape of microglia, depending on the APOE isoform expressed. The most pronounced differences were between APOE2 and APOE4 microglia.
APOE4 microglia showed increased production of cytokines, signaling molecules involved in immune regulation, and a reduced capacity to migrate and shift into protective states. They were also less effective at phagocytosis, the process of clearing debris and pathogens.
Conversely, APOE2 microglia exhibited increased expression of genes that promote microglia proliferation and migration, along with a decreased inflammatory immune response. Additionally, APOE2 microglia showed increased DNA-binding of the vitamin D receptor. Low vitamin D levels have been linked to a higher incidence of Alzheimer’s.
The study underscores that microglia responses to amyloid pathology vary significantly across APOE versions. Considering the interplay between genetic risk factors and microglial states is critical in understanding disease progression. The research also highlights the potential role of the vitamin D receptor, offering new avenues for therapeutic exploration in addressing the APOE gene’s role in Alzheimer’s.
“Our findings emphasise that ther is a complex interplay between genetic, epigenetic, and environmental factors that influence microglial responses in Alzheimer’s disease,” said Dr. Sarah Marzi, Senior Lecturer in Neuroscience at King’s College London. “Our research suggests that microglia expressing the risk-increasing APOE4 variant are not as effective at mounting protective microglial functions, including cell migration, phagocytosis and anti-inflammatory signalling. This underscores the need for targeted interventions based on APOE genotype.”
What’s next
Future research will likely focus on developing therapies that target specific APOE isoforms to enhance microglia function and reduce the risk of Alzheimer’s disease. Further investigation into the role of vitamin D and its receptor may also yield new preventative strategies.